Trial Profile
A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Pharmacokinetics; Therapeutic Use
- 24 Jul 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 24 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 28 Dec 2022 Status changed from recruiting to active, no longer recruiting.